New York, USA, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Market to Showcase Remarkable Growth at a CAGR of 12.4% by 2034 | DelveInsight According to DelveInsight’s analysis, the growth of the hidradenitis suppurativa market is expected to be mainly driven by the rise in awareness and access to treatment, recent approval of biologic therapies, anticipated approval of JAK-inhibitors & nanobodies and robust pipeline activity in the 7MM.
DelveInsight’s Hidradenitis Suppurativa Market Insights report includes a comprehensive understanding of current treatment practices, emerging hidradenitis suppurativa drugs, market share of individual therapies, and current and forecasted hidradenitis suppurativa market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Hidradenitis Suppurativa Market Report Hidradenitis suppurativa market is currently underserved. It is anticipated that similar to rheumatoid arthritis, hidradenitis suppurativa has a sufficiently large market potential to support the co-existence of several blockbuster medications.
According to DelveInsight’s analysis, the market size of hidradenitis suppurativa in the 7MM was USD 1.4 billion in 2023 and it is expected to increase by 2034. The total prevalent cases of hidradenitis suppurativa in the 7MM were approximately 6.
2 million cases in 2023. Prominent companies working in the domain of hid.
